

Nanoscale

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: Q. Pham, J. Glicksman and A. Chatterjee, *Nanoscale*, 2024, DOI: 10.1039/D4NR01300J.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

No relevant data is associated with this minireview

Open Access Article. Published on 18 Haziran 2024. Downloaded on 29/06/2024 03:32:54.
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.



Chemical approaches to probe and engineer AAV vectors

Quan Pham, Jake Glicksman, and Abhishek Chatterjee*

Department of Chemistry, Boston College, 2609 Beacon Street, Chestnut Hill, MA 02467, USA

*Corresponding author. E-mail address: abhishek.chatterjee@bc.edu



Abstract

Adeno-associated virus (AAV) has emerged as the most promising vector for *in vivo* human gene therapy, with several therapeutic approvals in the last few years and countless more under development. Underlying this remarkable success are several attractive features that AAV offers, including lack of pathogenicity, low immunogenicity, long-term gene expression without genomic integration, the ability to infect both dividing and non-dividing cells, etc. However, the commonly used wild-type AAV capsids in therapeutic development present significant challenges, including inadequate tissue specificity and the need for large doses to attain therapeutic effectiveness, raising safety concerns. Additionally, significant preexisting adaptive immunity against most natural capsids, as well as the development of such anti-capsid immunity after the first treatment, represent major challenges. Strategies to engineer the AAV capsid are critically needed to address these challenges and unlock the full promise of AAV gene therapy. Chemical modification of the AAV capsid has recently emerged as a powerful new approach to engineer its properties. Unlike genetic strategies, which can be more disruptive to the delicate capsid assembly and packaging processes, “late-stage” chemical modification of the assembled capsid — whether at natural amino acid residues or site-specifically installed noncanonical amino acid residues — often enables a versatile approach to introducing new properties to the capsid. This review summarizes the significant recent progress in AAV capsid engineering strategies, with a particular focus on chemical modifications in advancing the next generation of AAV-based gene therapies



Introduction

Adeno-associated virus (AAV) is a small, non-enveloped virus belonging to the parvoviridae family, which has exhibited tremendous potential as a vector for the development of human gene therapies.[1-7] With 12 distinct human serotypes, none of which are linked to any human disease, AAV efficiently transduces a broad spectrum of both dividing and non-dividing cells, allowing for the prolonged expression of transgenes. Furthermore, AAV triggers minimal innate immune responses and is inherently replication deficient. Thanks to these attractive features, AAV stands out as a highly favorable vector for gene delivery in both *in vitro* and *in vivo* settings. To date, the FDA has approved five AAV-based drugs for gene therapy that address various genetic diseases:[8-13] Luxturna, an AAV2 drug for inherited retinal disease; Zolgensma, an AAV9 drug for spinal muscular dystrophy; Hemgenix, an AAV5 drug for hemophilia B; Roctavian, an AAV5 drug for hemophilia A; and Elevidys, an AAVrh74 drug to treat Duchenne muscular dystrophy. Numerous other clinical trials are underway, showing promising results.[3]

AAV possesses a compact genome, approximately 4.7 kb of single-stranded DNA flanked by two inverted terminal repeats (ITR).[6,14] The native genome features two main open reading frames —rep and cap — each of which produces multiple non-structured and structured proteins through alternative splicing and the use of alternative start codons. The capsid comprises three proteins, VP1, VP2, and VP3, approximately in a 1:1:10 ratio, forming an icosahedral particle with extensive interactions related to two-, three-, and five-fold symmetry.[14] The initial step in AAV's infectious pathway involves binding to a primary cell-surface receptor, followed by interaction with a secondary receptor.[15-17] This secondary interaction initiates diverse internalization pathways, resulting in trafficking to endosomal and Golgi compartments. Subsequently, AAV particles escape into the cytoplasm, accumulating in the perinuclear space before ultimately entering the nucleus for genome release and replication. These processes entail complex changes in capsid conformation and intricate interactions between the capsid and cellular factors, many of which remain poorly characterized. One of the main reasons behind this knowledge gap is the lack of appropriate tools to probe the biology underlying the entry of this virus. Many established tools used to probe protein localization and interaction network involve tagging the target with other proteins (e.g., proteins with intrinsic fluorescence or proximity labeling capabilities), which are typically incompatible with the delicate and complex AAV capsid. Consequently, new tools are



needed to elucidate the biology of AAV, which are associated with minimal perturbation to the target. In addition, recent advances in mass-spectrometry-based platforms have also revealed the presence of many novel post-translational modifications on the AAV capsid residues across multiple serotypes.[18,19] However, the distribution of these modifications is quite heterogeneous and, except for a few well-documented cases such as phosphorylation mediated capsid degradation,[20-22] and their physiological significance remains poorly understood.

Despite its remarkable success over the last decade, the wild-type AAV capsids that the industry and most clinical studies continue to rely on face several considerable disadvantages. One such key drawback is the limited control over the tissue tropism of native AAV serotypes. The broad tropism of AAV, affecting various tissues such as lung, liver, spleen, muscle, brain, kidney, etc., makes it challenging to deliver a transgene selectively to a target tissue. The liver, a common target for many AAV serotypes, acts as a sink, consuming the majority of delivered particles. Consequently, high doses of viral vectors are typically required to achieve sufficient transgene expression at the desired tissues, leading to potential toxicity in the liver and possibly other organs. Additionally, a large percentage of human population have AAV-neutralizing antibodies due to prior exposure to this virus, excluding them from AAV vector-based treatments. Furthermore, treatment of eligible patients with a particular therapeutic AAV vector typically triggers significant adaptive immune response, and the resulting neutralizing antibodies prevent subsequent redosing. To overcome these limitations, various strategies, including genetic engineering and chemical modification, have been employed to engineer the viral capsid of AAV.[1,2,6,23-29] In this review, we summarize these strategies, with a particular focus on the chemical approaches that have been utilized to both probe and engineer the biology of AAV.

An overview of the genetic approaches to engineer AAV

In this section we seek to provide a brief overview of the genetic approaches employed to engineer the properties of the AAV capsid, representative example of which are also summarized in Table 1. These examples can be broadly divided into two categories, those relying on rational engineering and on directed evolution. Rational design offers a more direct approach, and relies on prior knowledge of the structure and the function of the capsid to engineer the capsid proteins in a hypothesis-dependent manner. Such approaches typically involve rational mutation of residues



known to negatively impact AAV (e.g., phosphodegrons),[20-22] or the insertion of a peptide or a protein domain into permissive sites of the capsid proteins to introduce novel properties such as tissue specificity. Insertion of novel peptide sequences, such as those identified from *in vitro* selection experiments, into permissive loops of the AAV capsid proteins is straightforward, and has been used with some success for targeting the virus to specific cell-types.[30-35] However, permissive sites in the capsid that withstand such insertions are limited, and only small peptides are typically tolerated. Fusion of larger proteins – such as antibody fragments and DARPINs – has also been used, but these are largely restricted to the N-terminus, or into the variable domain IV of the minor capsid protein through extensive linker optimization.[36-43] Such strategies have also been used to improve the selectivity of AAV vectors. However, fusion of a foreign protein to the N-terminus of the minor capsid protein VP2 disrupts the natural capsid architecture, since VP2 N-terminus is normally tucked inside the capsid. Similarly, the disruptive effect of internal fusion on the capsid has also significantly limited the size and complexity of proteins that can be amenable to such fusion. Although there are numerous examples of using peptide and protein fusion strategies to engineer AAV, potential disruption to the complex and delicate capsid architecture represents a potential limitation of this strategy. Another notable rational approach involves the use of bispecific antibodies, which can mediate the interaction between an AAV capsid and a target receptor.[44,45] Insertion of peptide tags into the capsid, which can be subsequently covalently (e.g., formylglycine, HUH etc.), or noncovalently (e.g., asymmetric leucine zippers) labeled with function-altering entities with high specificity, has also been employed to engineer the properties of the capsid. [46-50]

Directed evolution approaches have been extensively utilized to create AAV variants with enhanced capabilities such as selective transduction of specific tissues and evading neutralizing antibodies. Several approaches have been used to generate the libraries of capsid variants for such directed evolution experiments, including error-prone mutagenesis of the cap gene,[51-53] DNA shuffling of the cap gene from various existing AAV serotypes,[54-57] as well as the insertion of randomized peptide libraries into a permissive site of the capsid (e.g., at the variable domains IV and VIII of the capsid).[58-66] Facilitated by the available structural information of the AAV capsid, and the rapid development of DNA synthesis and next-generation sequencing capabilities, numerous AAV directed evolution studies have been reported in both cell cultures and animal models. This process has successfully generated variants capable of efficiently transducing



challenging targets such as the brain, muscles, and T cells while exhibiting lower immunogenicity, which are excellent potential candidates for gene therapy. Despite these success stories, directed evolution of AAV capsid can be a time- and labor-intensive process, which is not guaranteed to yield desirable results. Moreover, mutant capsids with novel properties selected using a specific setup (in cell culture or non-human animal models) may not always translate to humans, due to subtle differences in receptor structures other factors *in vivo*.

Finally, *in silico* engineering of the AAV capsid has recently emerged as a promising alternative approach. For example, machine learning strategies, that capitalize large sequence-function correlation datasets, such deep-mutation profiling data of the AAV capsid gene, are being used to design novel capsid mutants.[67,68] Computational approaches have also been used to resurrect extinct ancestral AAV capsid sequences, which may have limited preexisting immunity.[69,70]

Table 1: Summary of major genetic strategies to engineer AAV

Strategies	Selected Methods	Advantages	Disadvantages	References
Directed evolution	Error-prone PCR	Enables diversification across the whole capsid. Can find unexpected mutations which improve function	Low mutation rate in library generation, Limited coverage of the possible sequence space	[51-53]
	Serotype shuffling	Combines the benefits of multiple serotypes. Enables protein fusions at logical break points	Unlikely to acquire novel and unique functions	[54-57]
	AAV display	Allows <i>in vivo</i> selection of cell-binding peptides incorporated in the capsid	Selections are technically demanding, outcome is unpredictable	[58-66]
	Structure-guided approach	Can be used on any serotype to retarget virus to tissue of interest Evolved variants can gain altered tissue tropism and immune evasion	Requires relevant structural information.	[71,72]
Rational Design	Point mutation to ablate phospho-	Improves both <i>in vitro</i> and <i>in vivo</i> transduction abilities via point	Limited scope	[20-22]



	degrons on the Capsid Surface	mutations (such as tyrosine residues)		
	Peptide Loop Insertion	Can be well tolerated at specific sites, Straightforward approach	May destabilize the capsid in most sites, limited to short peptides,	[30-35]
	N-terminal fusion and loop insertion to Minor Capsid Proteins	Can be used to attach larger, folded protein domains (such as affibodies and DARPin)	Can disrupt capsid, and thus infectivity and viral titer	[36-43]
	Non-covalent modification using biochemical tags	Can be used to attach small to large, folded proteins (antibodies, protein vault nanoparticles)	Some bacteria-derived tags can be immunogenic <i>in vivo</i> Non-covalent conjugation can cause loss of the attached molecules.	[46-50]
<i>In silico</i> design	Computational reconstruction of Ancestral AAVs	Allows discovery of ancestral capsids that are not recognized by the immune system	Unpredictable tropism. Acquires adaptive immune response after first dose	[69,70]
	Machine-learning assisted capsid evolution	Diverse, synthetic capsid variants can be generated with higher throughput than rational design and random mutagenesis approaches	Requires necessary machine learning models and algorithms Require library cloning capable of covering the vast amount of generated variants	[67,68]

Chemical modification of the AAV capsid

Genetic approaches to engineer AAV are typically associated with significant sequence alterations (mutation or insertions) which may have unanticipated impacts on the complex structure and biology of AAV. These concerns are further amplified by our limited understanding of AAV biology, which compromises our ability to fully map the associated impacts of such sequence changes. Chemical modification of native AAV capsids, or those harboring site-specifically incorporated bioorthogonal conjugation handles, has emerged as an alternative approach for introducing function-altering entities on them to engineer their properties. Chemical modification



has also been used to introduce small biophysical probes on the capsid to study the biology of AAV. Since the modification is introduced on packaged capsids, this strategy largely maintains the native capsid architecture and packaging behavior of AAV. The degree of capsid modification can also be carefully controlled by modulating reaction conditions to avoid introducing perturbation to its structure and function. Furthermore, this approach allows the introduction of entities with practically unlimited chemical diversity on the AAV capsid, enabling the creation of diverse AAV conjugates with novel properties. This includes user-defined synthetic molecules, fluorescent dyes, quantum dots, DNA, RNA, peptides, and even proteins. The resulting conjugates have many potential applications such as: 1) aiding the virus in evading the immune system, 2) retargeting the virus to tissues of interest with high efficiency and selectivity, 3) studying the biology of the virus through real-time imaging and controlling its behavior with light, and 4) using the virus as a tool for the directed evolution of biomolecules. Below, we discuss the advances in this area, focusing first on the modification of native AAV capsids at canonical amino acid residues, and then bioorthogonal site-specific modification of AAV capsids harboring precisely incorporated noncanonical amino acid residues.

Modification of the AAV capsid at canonical amino acid residues

Advances in protein-labeling chemistries provide numerous ways to modify the capsid proteins at various canonical amino acid residues with high chemoselectivity, including lysine, arginine, cysteine, and tyrosine residues with no genetic manipulation needed.

Utilizing lysine residues

Earlier work on chemical modification of AAV has centered around the surface exposed lysine residues on the viral capsid.^{33–37} [73-77] Due to the nucleophilicity of the lysine side-chain, it is possible to acylate the amino groups with either N-hydroxysuccinimide (NHS) esters or isothiocyanates in buffered aqueous solutions near physiological pH. In an effort to understand how AAV invades the cell, early research used lysine-selective NHS esters to introduce fluorescent cyanine dyes on the capsid. These probe-labeled virus particles allowed the real time imaging of viral entry into live cells.[73-76] Such experiments provided initial knowledge about the kinetics of AAV entry and trafficking. This strategy has also been used to introduce other probes such as



quantum dots, which are less susceptible to photobleaching, as well as radioactive isotopes (which was attached to AAV by NHS-tetrazine, followed by TCO ligation), enabling other ways to probe AAV entry and trafficking.[78-81]

Additionally, lysine-targeted NHS ester chemistry was also used by the Schaffer group to attach polyethylene glycol (PEG) to AAV to shield the virus from the immune system.[82] Various PEG lengths were appended to uncover the optimal shielding effect against neutralizing antibodies in serum. By testing multiple virus:PEG ratios, the study underscored the importance of regulating capsid modification levels to achieve optimal shielding without compromising viral infectivity. Similarly, the Jiang group tethered an immunosuppressive zwitterionic phosphoserine (PS)-containing polypeptide as an immunomodulatory signal to the viral capsid.[83] The resulting conjugates were observed to significantly diminish anti-AAV immune responses without substantially altering viral transduction and tropism. Kwon *et al.* conjugated AAV with eosin (a photo-initiator) at surface-exposed lysine residues using isothiocyanate, [84] which was subsequently used to initiate a polymerization reaction to create an acid-degradable polyketal shell around the virus, which was further embedded with siRNAs. This polymer-coated virus evaded immune response while co-delivering both the virus and the siRNA into cells. In a different approach, Ayuso *et al.* employed isothiocyanate chemistry to attach carbohydrates as hepatocyte-targeting moieties.[85]

To develop a more universal platform, streptavidin or biotin was conjugated to the AAV capsid using NHS reagents. Taking advantage of the rapid and near-irreversible association between biotin and avidin, the platform allowed the attachment of various biomolecules of interest to the AAV capsids which was chemically conjugated with either of the two. For example, Lee and Ahn demonstrated that AAV2 modified with streptavidin–NHS ester can be noncovalently linked to biotin-tagged antibodies.[86] The anti-EpCAM-AAV2 conjugates exhibited remarkable specificity in targeting and slowing tumor progression in mouse models by transporting EGFR shRNA. In an alternative approach, the Castillas, Jr. team engineered AAV2 by introducing biotin-NHS, then coupling it with EGF-Streptavidin fusion, resulting in over a 100-fold increase in transduction in SK-OV-3 cells. Similarly, Rao *et al.* employed biotin-labeled AAV along with T4 phage, connected through a streptavidin bridge, yielding a hybrid vector capable of carrying unprecedented payloads of up to 170 kb DNA genome and up to 1025 protein molecules. Although



this approach is valuable, a downside of this strategy includes the poor control over attachment site and stoichiometry. Potential immunogenicity associated with bacteria-derived avidin is also a concern.

Utilizing arginine residues

Many serotypes of AAV utilize positively charged arginine residues to bind heparan sulfate proteoglycan for cellular entry. Alterations to these arginine residues can ‘detarget’ the virus from its primary receptor for reengineering AAV tropism. Asokan *et al.* demonstrated the feasibility of masking surface-exposed arginines of AAV2 using methylglyoxal, generating charge-neutral hydroimidazolones and thereby disrupting viral binding to heparan sulfate.[87] This led to the observed ability to evade neutralizing antibodies, along with introducing novel tissue tropism towards cardiac and skeletal muscle. Similarly, Pearce *et al.* glycated arginine residues with 4-azidophenyl glyoxal, introducing a click chemistry handle to the AAV6 capsid.[88] The azide group reacts with BCN through strain-promoted azide-alkyne cycloaddition (SPAAC), facilitating the crosslinking of anti-VCAM1-scFv to the virus as a retargeting agent. Similar to lysine residues, targeting arginine residues also faces intrinsic challenges in controlling the site of attachment and the right degree of modification to optimize AAV conjugate. Disruption of the endogenous net charge of AAV, as well as the cross-reactivity of methylglyoxal with other nucleophilic residues can also be problematic.

Utilizing tyrosine residues

In addition to modifying lysine and arginine, tyrosine-selective conjugation reactions have also been used to modify AAV. Targeting tyrosine residues is advantageous because, unlike lysine and arginine-selective reactions, tyrosine modification is typically not associated with a change in charge, minimizing the chances of perturbing virus structure and function. In addition, tyrosine residues are less abundant than lysine and arginine on the capsid, affording a lower degree of heterogeneity when chemically modified. Leveraging the unique redox properties of the tyrosine phenol, Asokan and colleagues used a mild metal-catalyzed oxidation reaction to crosslink a pair of neighboring tyrosine residues bridging two capsid proteins together.[89] This selective crosslinking reaction was used to probe the role of interfacial dynamics at the AAV capsid's two-




fold symmetry axis, in the externalization of N-terminal domain of a capsid protein during infection. Recently, a novel tyrosine-selective electrochemical conjugation strategy was developed by Gouin *et al.* using N-methyluminol derivatives.[90] The tyrosine residues of AAV2 were used to attach carbohydrates such as acetylgalactosamine (GalNAc) or mannose (Man) as retargeting moieties.[91] Alternatively, Mével *et al.*, have utilized the azo-coupling reaction to label tyrosine residues on the AAV capsid to attach carbohydrates for selective transduction of liver and retinal targets.[92]


Utilizing cysteine residues

A key limitation of targeting canonical amino acids for protein labeling is the limited control over site and stoichiometry. Due to the relative scarcity of cysteines in proteins, coupled with its unique reactivity as a potent nucleophile, engineered cysteine residues have been frequently used for labeling proteins with improved site-specificity. Given the lack of exposed cysteine residues in AAV capsids, the introduction of engineered cysteine residues represents an attractive strategy for site-specific and stoichiometry control capsid modification. However, use of this strategy has remained relatively rare for AAV capsid engineering, possibly due to associated technical challenges such as oxidation of the exposed cysteines, as well as potential capsid aggregation. The Azzouz lab incorporated a 12-amino acid tetracysteine motif into the interface of VP1/VP2 proteins of AAV9.[93] After packaging, the disulfide bonded cysteine residues were reduced with TCEP, yielding nucleophilic thiols, followed by labeling with maleimide-containing molecules. Using this strategy, fluorescent dyes were attached to the capsid, enabling real-time *in vivo* imaging of viral particles in the mouse brain. Additionally, by conjugating the virus with biotin to enable streptavidin enrichment, it was possible to identify potential host interaction partners, including actin/cytoskeletal proteins, proteins involved in RNA splicing/processing, chromatin modification, intracellular trafficking, etc.





Subsequent chemical reactions to attach molecule of interest



- Modification of Lys
- Modification of Arg
- Modification of Cys
- Modification of Tyr
- Molecule to be attached

Figure 1: Various chemistry on canonical amino acids to engineer the AAV capsid



Table 2: Strategies for chemical modification of AAV at canonical amino acid residues

Amino acid to modify	AAV serotype	Reagent and chemistry to modify	Molecule to be attached	Application	Reference
Lys	AAV2 AAV3 AAV9 AAVrh .10	N-Hydroxy-succinimide (NHS)	Fluorescence dyes	FACS analysis, real time imaging, Real-time single particle tracking during infection	[73-76]
			Quantum dot	Long-term live-cell imaging	[78]
			Radioactive isotope	Imaging in animal models	[79-81]
			Polyethylene glycol	Vector protection against neutralizing antibodies	[82]
			Paclitaxel	Delivery of taxol	[94]
			Biotin	Noncovalently conjugate with streptavidin – EGF fusion protein, or with T4 phage	[95, 96]
			Streptavidin	Noncovalently conjugate with biotin tagged antibody for retargeting	[86]
AAV8	NHS followed by maleimide	zwitterionic phosphoserine	Suppress preexisting immunity by evading anti-AAV antibodies	[83]	
AAV8	3,3'-dithiobis(sulfo-succinimidyl propionate) (DTSSP)	L-fucose, cross-linked AAV	Targeted gene delivery in pancreatic cancer cells	[97]	
AAV2, AAV8	Isothiocyanates	FITC, GalNac, Mannose	Live-cell imaging, Targeted delivery to hepatocytes	[85]	
		Eosin to trigger photopolymerization	Encapsulate AAV in an acid-degradable polymeric shell embedded with siRNA for 1) gene and siRNA co-delivery and 2) immune-evasion	[84]	
AAV2, AAV8, AAV9	N-ethyl Maleimide (NEM)		Retargeting to murine bone marrow	[98]	



Arg	AAV2	Methylglyoxal	Hydroimidazol -ones	- Retarget from liver to skeletal and cardiac muscle - Immune evasion	[87]
	AAV2	4-azidophenyl glyoxal, followed by BCN (via SPAAC)	Anti V-CAM1 scFv	Retargeting to endothelial cells	[88]
Tyr	AAV2	MMPP	Cross-linked VP protein	Investigation the impact of inter- subunit protein dynamics on externalization of VP N-terminus	[89]
	AAV2	Diazonium Salts	GalNac, Mannose	Targeted delivery to hepatocytes and retina	[92]
	AAV2	N- methylluminol	GalNac, Mannose	Improved transduction of hepatocyte carcinoma	[91]
Cys	AAV9	TCEP, followed by maleimide	Fluorescence dye, biotin	<i>In vivo</i> imaging Characterization of the capsid interactome	[93]

Chemical modification of AAV capsid on non-canonical amino acids

Although labeling canonical amino acid residues have been used extensively, this approach provides limited control over the sites and stoichiometry of capsid modification, and typically results in heterogeneous mixture of conjugates. The lack of site-specificity also may be problematic due to modification of functionally important residues. The genetic code expansion technology (GCE) provides an exciting solution to these challenges by enabling site-specific incorporation of a noncanonical amino acid (ncAA) into the virus capsid with a bioorthogonal conjugation handle, which can be subsequently labeled with high specificity.

Production of AAV incorporating genetically encoded ncAAs

Using the genetic code expansion (GCE) technology, numerous ncAAs have been genetically encoded in various domains of life.[99-101] This technology uses an engineered aminoacyl-tRNA synthetase (aaRS)/tRNA pair to incorporate a ncAA in response to a repurposed nonsense codon (typically the amber stop codon UAG). With access to >200 ncAAs in mammalian cells, including those suitable for diverse applications such as bioorthogonal conjugation and photo-crosslinking. Their small structural footprint minimizes potential perturbation to the virus capsid, while providing powerful new capabilities to probe and engineer its properties.



Using the GCE technology, our lab and others have generated AAVs site-specifically decorated with ncAAs, through transient transfection of AAV2 genes, adenovirus helper genes, and a suitable aaRS/tRNA pair in mammalian cells.[102-105] To incorporate ncAA into the capsid protein, a stop codon is strategically placed at a surface-exposed site, which is suppressed by the engineered aaRS/tRNA pair. Since all capsid proteins VP1, VP2, VP3 share the same coding sequence with different splicing and alternative starts, introducing a stop codon at the common VP3 region results in the ncAA incorporation at all 60 capsid proteins. Using the pyrrolysyl synthetase (PylRS)/tRNA pair, it has been possible to incorporate azido-lysine (AzK) at various sites on the AAV capsid, without perturbing its properties. The azide-containing side chain of this ncAA enables subsequent bioorthogonal modification of the resulting capsids.

Recently, we developed a split-cap system to selectively incorporate the ncAA into a chosen subset of the capsid proteins (VP1, VP2, and VP3), providing further control over the number of ncAA handles present per capsid; capsids with 5 or 10 or 60 ncAAs can be generated by selectively incorporating them into capsid proteins VP1/VP2, VP1+VP2 or all VP1+VP2+VP3. [106] Additionally, the incorporation of ncAAs at minor capsid proteins was shown to provide wild-type-like titer of the recombinant virus, while also showing a greater tolerance to chemical modification with more defined conjugates.

Retargeting AAVs using site-specific capsid modification

It has been possible to retarget AAV to distinct cell surface receptors by attaching targeting ligands at ncAA residues on the capsid. For example, bioorthogonal attachment cyclic-RGD peptides onto AzK-modified AAV2 capsids using strain-promoted azide-alkyne cycloaddition has been used to selectively redirect them to cancer cell lines overexpressing integrin receptors.[102-106] A key advantage of this strategy is the ability to systematically modulate the site and stoichiometry of ligand attachment to fine-tune the properties of the resulting conjugate. We have shown that the site of attachment indeed has a significant impact on the efficacy of the resulting capsid conjugates. The number of retargeting ligands attached per capsid is also critically important. For example, cyclic-RGD mediated retargeting was found to be optimal at a labeling density of approximately 12 ligands/capsid.[106] Lower stoichiometry was insufficient for strong retargeting, likely due to inefficient binding, while excessive modification with cRGD was detrimental for infectivity. Kay *et al.* has also functionalized various AAV serotypes at site-



specifically incorporated AzK residues with aptamers as retargeting ligands, and demonstrated significant improvement in transduction in cancer cell lines *in vitro* [107]. However, the efficacy of the aptamer-AAV conjugates was modest *in vivo* in animal models, perhaps due to the aptamers' instability in blood. There is thus a need to further explore the possibility of attaching retargeting moieties with high receptor binding affinity and stability. Additionally, Wang *et al.* demonstrated that incorporation AzK into specific sites of the AAV5 capsid alone enhanced their lung-specific transduction.[108] This work highlights how the incorporation of diverse chemistries represented in the GCE toolbox – even without further modification – can impact the properties of AAV.

Lower the immunogenicity of AAV

GCE technology has significantly enhanced the control over the site and stoichiometry of capsid modification. Using this strategy, PEG molecules with varying molecular weights have been attached onto different sites on the AzK-containing virus particle.[109] The resulting viruses exhibited an approximately 50% reduction in anti-AAV antibody generation upon intravenous administration. In a different approach, the Mali *et al.* incorporated AzK into the AAV-DJ capsid for further conjugation with oligonucleotides using copper click chemistry.[110] By complexing the resulting oligonucleotide-labeled capsids with lipofectamine (a cationic lipid based transfection agent), they showed that the resulting lipofectamine-coated capsids were effectively shielded from neutralizing serum.

Probing the biology of viruses

Using GCE, we have incorporated photo-activatable ncAAs into the capsid of AAV2. Incorporating a photocaged lysine (NBK), replacing key arginine residues (R588 or R585) crucial for binding the primary receptor heparan sulfate proteoglycan (HSPG) resulted in non-infective mutants which were unable to bind HSPG.[111] However, a brief irradiation fully uncaged the positively charged lysine residue, restoring the HSPG receptor binding and nearly full-infectivity of these mutants. Using this strategy, it should be possible to reversibly perturb distinct molecular interactions between the virus particle and various host factors to probe their roles during viral entry. Additionally, AzK-labeled AAV capsids have also been bioorthogonally labeled with fluorescent dyes, enabling real-time imaging of virus particles during cellular entry and intracellular trafficking.[112]



Despite its remarkable potential, functionalizing AAVs with ncAAs also have some drawbacks. This approach is technically demanding, and requires significant manipulation of the standard genetic machinery needed for AAV production. Incorporating ncAAs using nonsense suppression can also lead to a reduction in viral yield, particularly when the ncAA is incorporated across all 60 capsid proteins. In addition, despite their limited footprint, not all ncAAs are tolerated at all exposed sites on the AAV capsid. In fact, only AzK and its analogs have been successfully integrated into AAV to date using the pyrrolysyl pair. Expanding the variety of ncAAs that can be incorporated into AAVs will significantly broaden the scope of applications achievable through modifying ncAAs on AAVs.

Virus as a tool for directed evolution

Beyond exploring the biology and engineering of AAV for enhanced gene therapy, we recently showed that AAV can be used to perform directed evolution of tRNAs (and potentially other biomolecules) in mammalian cells.[113,114] In this process, the activity of an AAV-encoded library of UAG-suppressing tRNA variants is coupled to the expression of a UAG-encoding AAV Cap gene. Consequently, tRNA variants with higher activity enable the production of ncAA-labeled Cap protein, facilitating the packaging of the progeny virus displaying the bioorthogonal ncAA handle on its capsid, which are further enriched through bioorthogonal biotinylation, followed by avidin enrichment. This chemical modification/enrichment strategy to improve the stringency of the selection was crucial for its success. This strategy has already been used for successful engineering of pyrrolysyl[113,115] and bacterial leucyl tRNAs,[116] and it has tremendous potential to facilitate directed evolution of additional biomolecules in mammalian cells. Gratifyingly, the engineered tRNAs generated by this method significantly improved the efficiency of ncAA incorporation into the capsid of AAV, providing wild-type-like yields.






Figure 2: a) A general scheme demonstrating the site-specific incorporation of ncAAs into AAV capsid protein in mammalian cells using a nonsense-suppressing engineered aaRS/tRNA pair. b) Structure of ncAAs incorporated in the AAV capsid. c) Different chemistry on noncanonical amino acids to engineer the AAV capsid



Table 3: Chemical modification of AAV using GCE technology

Serotype	ncAA	Tested sites	Reagents and chemistry to modify	Application	References
AAV2	AzK	S261, S264, A266, Q325, Q325+1, D327, N381, Y444, R447, T450-R459, S452+1, G453+1, S492, Y500, F534, E548, E548+1, T573, S578, R585+1, N587, N587+1, S662, T454 (VP1/VP2 only or VP1+VP2)	DBCO (via SPAAC) DIBO (via SPAAC)	- Attach cRGD peptides for retargeting to ovarian cancer cell lines - Biotin attachment for VADER selection in mammalian cells - Attach cRGD peptides to improve transduction of glioblastoma cells - Optimizing PEG linker size and site of incorporation to reduce immunogenicity - Attachment of fluorescent probes for imaging	[103,104,106] [113-116] [105] [109] [112]
	NBK	R585, R588	Irradiation with 365 nm deca	- Perturbation of HSPG binding to control AAV infection with light	[111]
AAV5	AzK	D374, E381, T444, G455, V481, S485, S518, T539, S576, T577	DBCO (via SPAAC)	- Attachment of fluorescence dyes - Improve transduction of many cell lines (HEK293, HUH7, C2C12, A549) and tissues (lung, liver, heart, TA muscle)	[108]
AAV-DJ	AzK	R447, S578, N587, S662	Alkyne (via Cu-click)	- Attachment of fluorescence dye for imaging - Attachment of oligonucleotide to coat AAV with lipofectamine, shielding AAV from neutralizing serum	[110]
		T456, D555, A587, N589	DBCO (via SPAAC)	- Attachment of biotin for streptavidin blot	[107]



		N589 (VP2/VP3 only)		- Attachment of folic acid or aptamer for retargeting	
AAV8/ AAVL KO3	AzK	AAV8 (E330, T457, T499, N590, N590+1, AAV-LK03 (N588, T455, T456)	DBCO- (via SPAAC)	- Attach folic acid for improved transduction of HeLa cells	[107]

Conclusion

In this review, we have outlined various exciting strategies for modifying the capsid of AAV to understand and engineer its biology, especially for developing next-generation gene therapy vectors. Among these methods, we've particularly emphasized on the chemical approaches to modify the AAV capsid, either at canonical amino acid residues, or at site-specifically incorporated ncAA residues using the GCE technology. This approach allows the capsid to be decorated with diverse entities, including biophysical probes, peptides, proteins, sugars, oligonucleotides, carbohydrates, etc. to probe and manipulate AAV biology. Modification of the canonical amino acid residues provides a technically simple, yet enabling approach to modify the AAV capsid. However, this strategy is typically associated with a lack of control over the site of modification. Although technically more demanding, the site-specific ncAA incorporation technology offers a complementary strategy with an exquisite level of control over the site and stoichiometry of capsid modification. Recent results have underscored how such controlled modification is crucial for producing AAV conjugates with optimal properties. Further development of these strategies has the potential to overcome the existing hurdles in AAV gene therapy, including retargeting the virus to specific tissues and protecting it from the immune system, thereby fully harnessing the remarkable potential of this exciting new therapeutic modality.



Acknowledgement

AC acknowledges support from National Science Foundation (MCB-1817893) and NIH (R35GM136437)

Declaration of Interest: Authors declare no conflict of interest



References

1. Wang D, Tai PWL, Gao G: **Adeno-associated virus vector as a platform for gene therapy delivery.** *Nature Reviews Drug Discovery* 2019, **18**:358-378.
2. Li C, Samulski RJ: **Engineering adeno-associated virus vectors for gene therapy.** *Nature Reviews Genetics* 2020, **21**:255-272.
3. Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, van der Loo JCM, Johnstone EC: **The clinical landscape for AAV gene therapies.** *Nat Rev Drug Discov* 2021, **20**:173-174.
4. Samulski RJ, Muzyczka N: **AAV-Mediated Gene Therapy for Research and Therapeutic Purposes.** *Annu Rev Virol* 2014, **1**:427-451.
5. Naso MF, Tomkowicz B, Perry III WL, Strohl WR: **Adeno-associated virus (AAV) as a vector for gene therapy.** *BioDrugs* 2017, **31**:317-334.
6. Pupo A, Fernández A, Low SH, François A, Suárez-Amarán L, Samulski RJ: **AAV vectors: The Rubik's cube of human gene therapy.** *Mol Ther* 2022, **30**:3515-3541.
7. Mingozi F, High KA: **Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.** *Nature Reviews Genetics* 2011, **12**:341-355.
8. Keeler AM, Flotte TR: **Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?** *Annu Rev Virol* 2019, **6**:601-621.
9. Gao J, Hussain RM, Weng CY: **Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence.** *Clin Ophthalmol* 2020, **14**:3855-3869.
10. Blair HA: **Onasemnogene Apeparvovec: A review in spinal muscular atrophy.** *Cns Drugs* 2022, **36**:995-1005.
11. Heo Y-A: **Etranacogene dezaparvovec: first approval.** *Drugs* 2023, **83**:347-352.
12. Philippidis A: **BioMarin's ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A.** *Human Gene Therapy* 2023, **34**:665-668.
13. Hoy SM: **Delandistrogene Moxeparvovec: first approval.** *Drugs* 2023, **83**:1323-1329.
14. Agbandje-McKenna M, Kleinschmidt J: **AAV capsid structure and cell interactions.** *Methods Mol Biol* 2011, **807**:47-92.
15. Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH: **An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.** *J Virol* 2018, **92**.
16. Dhungel BP, Bailey CG, Rasko JEJ: **Journey to the Center of the Cell: Tracing the Path of AAV Transduction.** *Trends Mol Med* 2021, **27**:172-184.
17. Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, Jae LT, Wosen JE, Nagamine CM, Chapman MS, et al.: **An essential receptor for adeno-associated virus infection.** *Nature* 2016, **530**:108-112.
18. Mary B, Maurya S, Arumugam S, Kumar V, Jayandharan GR: **Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes.** *Febs j* 2019, **286**:4964-4981.
19. Guapo F, Strasser L, Millán-Martín S, Anderson I, Bones J: **Fast and efficient digestion of adeno associated virus (AAV) capsid proteins for liquid chromatography mass spectrometry (LC-MS) based peptide mapping and post translational modification analysis (PTMs).** *Journal of Pharmaceutical and Biomedical Analysis* 2022, **207**:114427.



20. Nakahama R, Saito A, Nobe S, Togashi K, Suzuki IK, Uematsu A, Emoto K: **The tyrosine capsid mutations on retrograde adeno-associated virus accelerates gene transduction efficiency.** *Mol Brain* 2022, **15**:70.
21. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Jr., Weigel-Van Aken KA, et al.: **Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.** *Proc Natl Acad Sci U S A* 2008, **105**:7827-7832.
22. Whitehead M, Sage A, Burgoyne T, Osborne A, Yu-Wai-Man P, Martin KR: **Immunobiology of a rationally-designed AAV2 capsid following intravitreal delivery in mice.** *Gene Ther* 2023, **30**:723-735.
23. Asokan A, Schaffer DV, Samulski RJ: **The AAV vector toolkit: poised at the clinical crossroads.** *Mol Ther* 2012, **20**:699-708.
24. Büning H, Srivastava A: **Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.** *Mol Ther Methods Clin Dev* 2019, **12**:248-265.
25. Lee EJ, Guenther CM, Suh J: **Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering.** *Curr Opin Biomed Eng* 2018, **7**:58-63.
26. Kotterman MA, Schaffer DV: **Engineering adeno-associated viruses for clinical gene therapy.** *Nature Reviews Genetics* 2014, **15**:445-451.
27. Becker J, Fakhiri J, Grimm D: **Fantastic AAV Gene Therapy Vectors and How to Find Them-Random Diversification, Rational Design and Machine Learning.** *Pathogens* 2022, **11**.
28. Wagner HJ, Weber W, Fussenegger M: **Synthetic Biology: Emerging Concepts to Design and Advance Adeno-Associated Viral Vectors for Gene Therapy.** *Adv Sci (Weinh)* 2021, **8**:2004018.
29. Zolotukhin S, Vandenberghe L: **AAV capsid design: A Goldilocks challenge.** *Trends in Molecular Medicine* 2022, **28**:183-193.
30. Büning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M: **Receptor targeting of adeno-associated virus vectors.** *Gene Ther* 2003, **10**:1142-1151.
31. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M: **Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.** *Nat Med* 1999, **5**:1438.
32. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N: **Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.** *J Virol* 2000, **74**:8635-8647.
33. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, Weitzman MD: **Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids.** *Mol Ther* 2001, **3**:964-975.
34. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH: **Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.** *Mol Ther* 2001, **4**:174-181.
35. Ried MU, Girod A, Leike K, Büning H, Hallek M: **Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors.** *J Virol* 2002, **76**:4559-4566.
36. Eichhoff AM, Börner K, Albrecht B, Schäfer W, Baum N, Haag F, Körbelin J, Trepel M, Braren I, Grimm D, et al.: **Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors.** *Mol Ther Methods Clin Dev* 2019, **15**:211-220.



37. Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, Buchholz CJ: **Displaying High-affinity Ligands on Adeno-associated Viral Vectors Enables Tumor Cell-specific and Safe Gene Transfer.** *Molecular Therapy* 2013, **21**:109-118.
38. Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, Trkola A, Plückthun A, Büning H, Buchholz CJ: **Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.** *Nat Commun* 2015, **6**:6246.
39. Yang Q, Mamounas M, Yu G, Kennedy S, Leaker B, Merson J, Wong-Staal F, Yu M, Barber JR: **Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy.** *Hum Gene Ther* 1998, **9**:1929-1937.
40. Hartmann J, Münch RC, Freiling RT, Schneider IC, Dreier B, Samukange W, Koch J, Seeger MA, Plückthun A, Buchholz CJ: **A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors.** *Mol Ther Methods Clin Dev* 2018, **10**:128-143.
41. Theuerkauf SA, Herrera-Carrillo E, John F, Zinser LJ, Molina MA, Riechert V, Thalheimer FB, Börner K, Grimm D, Chlanda P, et al.: **AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.** *Biomaterials* 2023, **303**:122399.
42. Hamann MV, Beschorner N, Vu XK, Hauber I, Lange UC, Traenkle B, Kaiser PD, Foth D, Schneider C, Büning H, et al.: **Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors.** *PLoS One* 2021, **16**:e0261269.
43. Michels A, Frank AM, Günther DM, Mataei M, Börner K, Grimm D, Hartmann J, Buchholz CJ: **Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8.** *Mol Ther Methods Clin Dev* 2021, **23**:334-347.
44. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ: **Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody.** *Nat Biotechnol* 1999, **17**:181-186.
45. Kuklik J, Michelfelder S, Schiele F, Kreuz S, Lamla T, Müller P, Park JE: **Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors.** *Int J Mol Sci* 2021, **22**.
46. Zdechlik AC, He Y, Aird EJ, Gordon WR, Schmidt D: **Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery.** *Bioconjug Chem* 2020, **31**:1093-1106.
47. Thadani NN, Yang J, Moyo B, Lee CM, Chen MY, Bao G, Suh J: **Site-Specific Post-translational Surface Modification of Adeno-Associated Virus Vectors Using Leucine Zippers.** *ACS Synth Biol* 2020, **9**:461-467.
48. Muik A, Reul J, Friedel T, Muth A, Hartmann KP, Schneider IC, Münch RC, Buchholz CJ: **Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer.** *Biomaterials* 2017, **144**:84-94.
49. Stachler MD, Chen I, Ting AY, Bartlett JS: **Site-specific Modification of AAV Vector Particles With Biophysical Probes and Targeting Ligands Using Biotin Ligase.** *Molecular Therapy* 2008, **16**:1467-1473.
50. Liu Y, Fang Y, Zhou Y, Zandi E, Lee CL, Joo KI, Wang P: **Site-specific modification of adeno-associated viruses via a genetically engineered aldehyde tag.** *Small* 2013, **9**:421-429.



51. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV: **Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.** *Nat Biotechnol* 2006, **24**:198-204.
52. Qian R, Xiao B, Li J, Xiao X: **Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity.** *Mol Ther Methods Clin Dev* 2021, **20**:122-132.
53. Koerber JT, Maheshri N, Kaspar BK, Schaffer DV: **Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles.** *Nat Protoc* 2006, **1**:701-706.
54. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leightle S, Redmond DE, Jr., et al.: **Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.** *Mol Ther* 2008, **16**:1252-1260.
55. Liu YB, Xu BC, Chen YT, Yuan X, Liu JY, Liu T, Du GZ, Jiang W, Yang Y, Zhu Y, et al.: **Directed evolution of AAV accounting for long-term and enhanced transduction of cardiovascular endothelial cells in vivo.** *Mol Ther Methods Clin Dev* 2021, **22**:148-161.
56. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA: **In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.** *J Virol* 2008, **82**:5887-5911.
57. Herrmann AK, Bender C, Kienle E, Grosse S, El Andari J, Botta J, Schürmann N, Wiedtke E, Niopek D, Grimm D: **A Robust and All-Inclusive Pipeline for Shuffling of Adeno-Associated Viruses.** *ACS Synth Biol* 2019, **8**:194-206.
58. Perabo L, Büning H, Kofler DM, Ried MU, Girod A, Wendtner CM, Enssle J, Hallek M: **In vitro selection of viral vectors with modified tropism: the adeno-associated virus display.** *Mol Ther* 2003, **8**:151-157.
59. Börner K, Kienle E, Huang LY, Weinmann J, Sacher A, Bayer P, Stüllein C, Fakhiri J, Zimmermann L, Westhaus A, et al.: **Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening.** *Mol Ther* 2020, **28**:1016-1032.
60. Körbelin J, Dogbevia G, Michelfelder S, Ridder DA, Hunger A, Wenzel J, Seismann H, Lampe M, Bannach J, Pasparakis M, et al.: **A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases.** *EMBO Mol Med* 2016, **8**:609-625.
61. Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus HA, Kleinschmidt JA, Müller OJ: **Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.** *Gene Ther* 2012, **19**:800-809.
62. Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, Wu WL, Yang B, Huber N, Pasca SP, et al.: **Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.** *Nat Biotechnol* 2016, **34**:204-209.
63. Lin R, Zhou Y, Yan T, Wang R, Li H, Wu Z, Zhang X, Zhou X, Zhao F, Zhang L, et al.: **Directed evolution of adeno-associated virus for efficient gene delivery to microglia.** *Nat Methods* 2022, **19**:976-985.
64. Ravindra Kumar S, Miles TF, Chen X, Brown D, Dobrova T, Huang Q, Ding X, Luo Y, Einarsson PH, Greenbaum A, et al.: **Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types.** *Nat Methods* 2020, **17**:541-550.
65. Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, Krunnusz A, Tavakoli S, Widrick JJ, Messemer KA, et al.: **Directed evolution of a family of AAV capsid**



- variants enabling potent muscle-directed gene delivery across species. *Cell* 2021, **184**:4919-4938.e4922.
66. Davidsson M, Wang G, Aldrin-Kirk P, Cardoso T, Nolbrant S, Hartnor M, Mudannayake J, Parmar M, Björklund T: **A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism.** *Proc Natl Acad Sci U S A* 2019, **116**:27053-27062.
67. Ogden PJ, Kelsic ED, Sinai S, Church GM: **Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design.** *Science* 2019, **366**:1139-1143.
68. Bryant DH, Bashir A, Sinai S, Jain NK, Ogden PJ, Riley PF, Church GM, Colwell LJ, Kelsic ED: **Deep diversification of an AAV capsid protein by machine learning.** *Nat Biotechnol* 2021, **39**:691-696.
69. Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS, Andres-Mateos E, Shah S, Shelke R, Maurer AC, Plovie E, et al.: **In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector.** *Cell Rep* 2015, **12**:1056-1068.
70. Zinn E, Unzu C, Schmit PF, Turunen HT, Zabaleta N, Sanmiguel J, Fieldsend A, Bhatt U, Diop C, Merkel E, et al.: **Ancestral library identifies conserved reprogrammable liver motif on AAV capsid.** *Cell Rep Med* 2022, **3**:100803.
71. Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A: **Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.** *Proc Natl Acad Sci U S A* 2017, **114**:E4812-e4821.
72. Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WH, Allain V, Steinhart Z, et al.: **An evolved AAV variant enables efficient genetic engineering of murine T cells.** *Cell* 2023, **186**:446-460.e419.
73. Bartlett JS, Samulski RJ: **Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy.** *Nat Med* 1998, **4**:635-637.
74. Bartlett JS, Samulski RJ, McCown TJ: **Selective and rapid uptake of adeno-associated virus type 2 in brain.** *Hum Gene Ther* 1998, **9**:1181-1186.
75. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF: **Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.** *J Virol* 2000, **74**:9184-9196.
76. Seisenberger G, Ried MU, Endress T, Büning H, Hallek M, Bräuchle C: **Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.** *Science* 2001, **294**:1929-1932.
77. Xiao W, Warrington KH, Jr., Hearing P, Hughes J, Muzyczka N: **Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2.** *J Virol* 2002, **76**:11505-11517.
78. Joo KI, Fang Y, Liu Y, Xiao L, Gu Z, Tai A, Lee CL, Tang Y, Wang P: **Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates.** *ACS Nano* 2011, **5**:3523-3535.
79. Kothari P, De BP, He B, Chen A, Chiuchiolo MJ, Kim D, Nikolopoulou A, Amor-Coarasa A, Dyke JP, Voss HU, et al.: **Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors.** *Sci Rep* 2017, **7**:39594.
80. Seo JW, Ingham ES, Mahakian L, Tumbale S, Wu B, Aghevlian S, Shams S, Baikoghli M, Jain P, Ding X, et al.: **Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation.** *Nat Commun* 2020, **11**:2102.



81. Zengel J, Wang YX, Seo JW, Ning K, Hamilton JN, Wu B, Raie M, Holbrook C, Su S, Clements DR, et al.: **Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression.** *Nat Methods* 2023, **20**:1070-1081.
82. Lee GK, Maheshri N, Kaspar B, Schaffer DV: **PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization.** *Biotechnol Bioeng* 2005, **92**:24-34.
83. Yuan Z, Li B, Gu W, Luozhong S, Li R, Jiang S: **Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide.** *J Am Chem Soc* 2022, **144**:20507-20513.
84. Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman DA, Kwon YJ: **Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.** *ACS Nano* 2016, **10**:8705-8714.
85. Mével M, Bouzelha M, Leray A, Pacouret S, Guilbaud M, Penaud-Budloo M, Alvarez-Dorta D, Dubreil L, Gouin SG, Combal JP, et al.: **Chemical modification of the adeno-associated virus capsid to improve gene delivery.** *Chem Sci* 2019, **11**:1122-1131.
86. Lee S, Ahn HJ: **Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.** *Acta Biomater* 2019, **91**:258-269.
87. Horowitz ED, Weinberg MS, Asokan A: **Glycated AAV vectors: chemical redirection of viral tissue tropism.** *Bioconjug Chem* 2011, **22**:529-532.
88. Pearce HA, Qian H, Connell TU, Huang D, Gottstein C, Donnelly PS, Peter K, Gregorevic P, Hagemeyer CE: **Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium.** *Mol Ther Methods Clin Dev* 2019, **14**:261-269.
89. Horowitz ED, Finn MG, Asokan A: **Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection.** *ACS Chem Biol* 2012, **7**:1059-1066.
90. Alvarez-Dorta D, Thobie-Gautier C, Croyal M, Bouzelha M, Mével M, Deniaud D, Boujtita M, Gouin SG: **Electrochemically Promoted Tyrosine-Click-Chemistry for Protein Labeling.** *J Am Chem Soc* 2018, **140**:17120-17126.
91. Depienne S, Bouzelha M, Courtois E, Pavageau K, Lalys PA, Marchand M, Alvarez-Dorta D, Nedellec S, Marín-Fernández L, Grandjean C, et al.: **Click-electrochemistry for the rapid labeling of virus, bacteria and cell surfaces.** *Nat Commun* 2023, **14**:5122.
92. Leray A, Lalys PA, Varin J, Bouzelha M, Bourdon A, Alvarez-Dorta D, Pavageau K, Depienne S, Marchand M, Mellet A, et al.: **Novel chemical tyrosine functionalization of adeno-associated virus improves gene transfer efficiency in liver and retina.** *Biomed Pharmacother* 2024, **171**:116148.
93. Chandran JS, Sharp PS, Karyka E, Aves-Cruzeiro J, Coldicott I, Castelli L, Hautbergue G, Collins MO, Azzouz M: **Site Specific Modification of Adeno-Associated Virus Enables Both Fluorescent Imaging of Viral Particles and Characterization of the Capsid Interactome.** *Sci Rep* 2017, **7**:14766.
94. Wei F, McConnell KI, Yu TK, Suh J: **Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs.** *Eur J Pharm Sci* 2012, **46**:167-172.



95. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M, Jr.: **Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.** *J Virol* 2002, **76**:12900-12907.
96. Zhu J, Tao P, Mahalingam M, Sha J, Kilgore P, Chopra AK, Rao V: **A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells.** *Sci Adv* 2019, **5**:eaax0064.
97. Yoo S, Kang B, Oh S, Kim Y, Jang JH: **A Versatile Adeno-Associated Viral Vector Cross-Linking Platform Capable of Tuning Cellular Tropisms and Simultaneously Inducing Solid-Phase Gene Delivery.** *ACS Appl Bio Mater* 2020, **3**:4847-4857.
98. Mulcrone PL, Lam AK, Frabutt D, Zhang J, Chrzanowski M, Herzog RW, Xiao W: **Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism.** *Sci Rep* 2023, **13**:8436.
99. Chin JW: **Expanding and reprogramming the genetic code.** *Nature* 2017, **550**:53-60.
100. Italia JS, Zheng Y, Kelemen RE, Erickson SB, Addy PS, Chatterjee A: **Expanding the genetic code of mammalian cells.** *Biochemical Society Transactions* 2017, **45**:555-562.
101. Young DD, Schultz PG: **Playing with the molecules of life.** *ACS Chem Biol* 2018.
102. Kelemen RE, Erickson SB, Chatterjee A: **Synthesis at the interface of virology and genetic code expansion.** *Curr Opin Chem Biol* 2018, **46**:164-171.
103. Kelemen RE, Erickson SB, Chatterjee A: **Production and Chemoselective Modification of Adeno-Associated Virus Site-Specifically Incorporating an Unnatural Amino Acid Residue into Its Capsid.** *Methods Mol Biol* 2018, **1728**:313-326.
104. Kelemen RE, Mukherjee R, Cao X, Erickson SB, Zheng Y, Chatterjee A: **A Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno-Associated Virus.** *Angew Chem Int Ed Engl* 2016, **55**:10645-10649.
105. Zhang C, Yao T, Zheng Y, Li Z, Zhang Q, Zhang L, Zhou D: **Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery.** *Biomaterials* 2016, **80**:134-145.
106. Erickson SB, Pham Q, Cao X, Glicksman J, Kelemen RE, Shahraeini SS, Bodkin S, Kiyam Z, Chatterjee A: **Precise Manipulation of the Site and Stoichiometry of Capsid Modification Enables Optimization of Functional Adeno-Associated Virus Conjugates.** *Bioconjug Chem* 2024, **35**:64-71.
107. Puzzo F, Zhang C, Powell Gray B, Zhang F, Sullenger BA, Kay MA: **Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer.** *Mol Ther Nucleic Acids* 2023, **31**:383-397.
108. Chang H, Du A, Jiang J, Ren L, Liu N, Zhou X, Liang J, Gao G, Wang D: **Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice.** *Mol Ther Methods Clin Dev* 2023, **31**:101129.
109. Yao T, Zhou X, Zhang C, Yu X, Tian Z, Zhang L, Zhou D: **Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.** *Molecules* 2017, **22**.
110. Katrekar D, Moreno AM, Chen G, Worlikar A, Mali P: **Oligonucleotide conjugated multi-functional adeno-associated viruses.** *Sci Rep* 2018, **8**:3589.
111. Erickson SB, Mukherjee R, Kelemen RE, Wrobel CJ, Cao X, Chatterjee A: **Precise Photoremovable Perturbation of a Virus-Host Interaction.** *Angew Chem Int Ed Engl* 2017, **56**:4234-4237.



112. Zhang C, Zhou X, Yao T, Tian Z, Zhou D: **Precision Fluorescent Labeling of an Adeno-Associated Virus Vector to Monitor the Viral Infection Pathway.** *Biotechnol J* 2018, **13**:e1700374.
113. Jewel D, Kelemen RE, Huang RL, Zhu Z, Sundaresh B, Cao X, Malley K, Huang Z, Pasha M, Anthony J, et al.: **Virus-assisted directed evolution of enhanced suppressor tRNAs in mammalian cells.** *Nat Methods* 2023, **20**:95-103.
114. Jewel D, Pham Q, Chatterjee A: **Virus-assisted directed evolution of biomolecules.** *Curr Opin Chem Biol* 2023, **76**:102375.
115. Jewel D, Kelemen RE, Huang RL, Zhu Z, Sundaresh B, Malley K, Pham Q, Loynd C, Huang Z, van Opijnen T, et al.: **Enhanced Directed Evolution in Mammalian Cells Yields a Hyperefficient Pyrrolysyl tRNA for Noncanonical Amino Acid Mutagenesis.** *Angew Chem Int Ed Engl* 2024, **63**:e202316428.
116. Huang RL, Jewel D, Kelemen RE, Pham Q, Wang S, Roy SJS, Huang Z, Levinson SD, Sundaresh B, Miranda SE, et al.: **Directed evolution of a bacterial leucyl tRNA in mammalian cells for enhanced noncanonical amino acid mutagenesis.** *bioRxiv* 2024.

